Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced

Related Experiment Video

Updated: Aug 5, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K

Rikiya Taoka1, Masaki Kamada2, Kazuyoshi Izumi3

  • 1Department of Urology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. taoka.rikiya@kagawa-u.ac.jp.

International Journal of Clinical Oncology
|February 28, 2024
PubMed
Abstract

Insights

Enfortumab vedotin shows efficacy in urothelial cancer, but peripheral neuropathy, especially in the sural nerve, impacts outcomes. Early electrophysiological changes may predict neuropathy onset, guiding treatment adjustments for better safety and efficacy.

Area of Science:

  • Oncology
  • Neurology
  • Pharmacology

Background:

  • Enfortumab vedotin is a novel antibody-drug conjugate for advanced urothelial carcinoma.
  • It is used as a third-line therapy after platinum-based chemotherapy and immunotherapy resistance.
  • Peripheral neuropathy is a known side effect requiring investigation into its impact on treatment efficacy.

Purpose of the Study:

  • To evaluate the effect of enfortumab vedotin-related peripheral neuropathy on treatment efficacy.
  • To determine if early electrophysiological changes predict neuropathy onset.
  • To associate neuropathy with treatment outcomes in urothelial cancer patients.

Main Methods:

  • Prospective multicenter cohort study of 34 advanced urothelial carcinoma patients.
  • Assessment of overall response, progression-free survival, overall survival, and safety.
  • Nerve conduction studies in 11 patients to evaluate electrophysiological changes.

Main Results:

  • Overall response rate was 52.9%, with a median overall survival of 13.5 months.
  • Peripheral neuropathy occurred in 12.5% of patients, associated with higher response rates (83.3%).
  • Nerve conduction studies revealed significant reduction in nerve conduction velocity, particularly in sensory nerves and lower limbs, with the sural nerve most affected.

Conclusions:

  • Enfortumab vedotin demonstrates significant efficacy in advanced urothelial carcinoma.
  • Peripheral neuropathy, particularly sural nerve involvement, is linked to treatment response.
  • Monitoring sural nerve electrophysiology may be crucial for optimizing enfortumab vedotin therapy and patient safety.
Keywords:
Enfortumab vedotinNerve conduction studyPeripheral neuropathyUrothelial carcinoma

More Related Videos

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

7.4K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 109:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.5K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...